All In Biotech

Drug Trial Radar · NCT03896633

Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt

A BIOEQUIVALENCE STUDY OF THE GENERIC BRINZOLAMIDE 1% OPHTHALMIC SUSPENSION COMPARED TO REFERENCE LISTED DRUG AZOPT® (BRINZOLAMIDE) OPHTHALMIC SUSPENSION 1% IN SUBJECTS WITH PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION

Last checked: Nov 20, 2026Latest source record: May 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 637 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

637

Actual

Start

Feb 28, 2018

Primary completion

Nov 17, 2018

Study completion Nov 17, 2018

Sponsor

Lead sponsor
Bausch & Lomb IncorporatedIndustry
Sponsor type
Industry
First posted
Apr 1, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (investigator, outcomes assessor)
Primary purpose
Health services research
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this prospective study is to demonstrate the therapeutic equivalence of topical brinzolamide compared with AzoptTM

Conditions

  • Glaucoma
  • Open Angle or Ocular Hypertension

Interventions

  • brinzolamide 1% ophthalmic suspensionDrug

    brinzolamide 1% ophthalmic suspension

  • Azopt 1%Drug

    Azopt 1%, RLD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Intraocular Pressure (IOP)Time frame: 6 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Various

    Bridgewater, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.